Regeneron Pharmaceuticals, Inc. (REGN) - Market Capitalization to Book Value Ratio

Regeneron Pharmaceuticals, Inc. (REGN) - corporate logo

Regeneron Pharmaceuticals maintains an impeccable reputation in medicine due to the creation of life-saving drugs. The company independently develops its scientific base and production, engaging external contractors only for the final stages of testing. The VelocImmune technological platform and patent protection provide a robust competitive advantage. The GURU.Markets portal contains the current market-to-book ratio, where the indicator stands at 2.66.

Regeneron Corp (REGN) - Market-to-Book Ratio from 07/04/2022 to 10/30/2026

Regeneron Pharmaceuticals, Inc. (REGN) - metric breakdowns and financial figures

- market value and analyst target forecast:
Price Chart Regeneron Pharmaceuticals|REGN - Broker Consensus Forecast
- market capitalization indicators:
Market Capitalization Regeneron Inc.|REGN - Value Adjusted for Debt and Cash
- balance sheet net asset value indicators:
Book Value per Share Regeneron|REGN - Total Stockholders' Equity|Market Capitalization to Book Value Ratio regeneron.com|REGN - Company Total Assets
- business debt structure and liquidity details:
Debt to Equity Regeneron Pharmaceuticals|REGN - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio Regeneron Inc.|REGN - Company Cumulative Indebtedness|Debt to Book Capitalization Ratio Regeneron Inc.|REGN - Company Long-Term Loans and Borrowings|Company Short-Term Debts Regeneron|Quick Ratio regeneron.com
- earnings and valuation multiples indicators:
REGN - Annual Net Income
Fundamental company valuation:Regeneron Pharmaceuticals
Manufactured product of Regeneron Corp

This indicator reflects the market-to-book value premium, measuring the extent to which investors overvalue assets relative to their book value. Analyzing the historical market-to-book ratio confirms that the high premium for Regeneron Pharmaceuticals (REGN) is justified by its ownership of the VelocImmune platform and blockbuster patents, which create a fundamental defensive moat for the business.

Who Regeneron Pharmaceuticals competes with

iRhythm Technologies (IRTC) - Market Value to Book Value Ratio|Capitalization to Book Value Ratio LNTH|MLYS (Mineralys Therapeutics, Inc.) - Market Capitalization to Book Value Ratio|HTFL: Market Value to Book Value|Market Capitalization to Book Value Ratio KMTS|ESPR - Market-to-Book Ratio|Market Capitalization to Book Value Ratio AMRN (Amarin Corporation plc)|Market Capitalization to Book Value Ratio Anteris AVR|TNYA - Market Value to Book Value Ratio|Market Value to Book Value CVRX (CVRx Inc.)|MIST (Milestone Pharma) - Market Cap to Net Assets Ratio|CRDL: Market Cap to Book Value Multiple|Market Value to Book Value Ratio HeartBeam, Inc.|TENX: Market Value to Book Value|Market Capitalization to Book Value Ratio ADGM|BCDA - Market-to-Book Ratio|Market Capitalization to Book Value Ratio VTAK (Catheter Precision Corp)|Market Value to Equity Ratio ARCA Biopharma Inc|Acasti - Market Capitalization to Book Value Ratio|Market-to-Book Ratio aerovatetx.com|vervetx.com (VERV) - Market Value to Book Value Ratio|Capitalization to Book Value Ratio WINT